Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iNeo-Vac-P01
- Development stage
- Phase 1
- Lead developer
- Hangzhou Neoantigen Therapeutics
- Modality
- Peptides, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
iNeo-Vac-P01 is a personalized neoantigen peptide cancer vaccine designed to treat advanced solid tumors. It consists of patient-specific mutated long peptides that are immunogenic and unique to each patient's tumor. The vaccine is developed using bioinformatics analysis of whole-exome sequencing data from the patient's tumor and blood samples, allowing for the identification and synthesis of individualized neoantigens. Administered subcutaneously with an adjuvant (GM-CSF), it aims to elicit a T-cell-mediated immune response targeting tumor-specific mutations. Clinical studies have shown that iNeo-Vac-P01 is feasible, safe, and capable of inducing measurable immune responses in patients with various advanced malignancies[1][2][6]. The primary developer is Hangzhou Neoantigen Therapeutics.
- Brand names
- iNeo-Vac-P01iNeo-Vac-P-01iNeo-Vac-P 01
- Other names
- Neoantigen peptides vaccine - Hangzhou Neoantigen Therapeuticspersonalized neoantigen peptide vaccine iNeo-Vac-P01
02
Targets
MHC II (Major histocompatibility complex class II receptor)
Beyond the preview
Go deeper on iNeo-Vac-P01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iNeo-Vac-P01.